Relay Therapeutics Announces Full Dose Escalation Data For RLY-4008
Portfolio Pulse from Benzinga Newsdesk
Relay Therapeutics announced complete first-in-human dose escalation data for RLY-4008, an investigational FGFR2 inhibitor. The data from the Phase 1/2 ReFocus study in patients with FGFR2-altered cholangiocarcinoma and other solid tumors will be presented at the 2023 ASCO Annual Meeting.
May 25, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relay Therapeutics' RLY-4008 dose escalation data announcement may positively impact the company's stock in the short term.
The announcement of complete first-in-human dose escalation data for RLY-4008, an investigational FGFR2 inhibitor, is a significant milestone for Relay Therapeutics. The data presentation at the 2023 ASCO Annual Meeting may generate positive attention and potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100